glp-1 agonists and anesthesia Updated guidance for patients using GLP-1/GIP receptor Holding GLP-1 Agonists Prior to

The product is formulated to support healthy weight management

Their potential for disease modification and symptom relief, particularly in specific phenotypes, supports their further exploration as part of a personalized treatment approach.

The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.

Here, the authors review the physiological roles of GLP-1, the potential renoprotective mechanisms of incretin-based therapies and the available renal outcome data from clinical trials.

Alluloss Plus+ is a naturally sweet, low-calorie blend made with allulose, essential vitamins, minerals, and prebiotic fiber

The incretin hormone glucagon-like peptide 1 (GLP-1) has been implicated in the gutrenal axis and incretin-based therapies might reduce the burden of diabetic kidney disease